The specific binding of 3H-labeled -y-aminobutyric acid ([3H]GABA) to synaptic plasma membranes from rat brains was inhibited by various quinolonecarboxylic acid derivatives (quinolones), and these inhibitions were concentration dependent. The binding of [3HJmuscimol to GABAA sites was also inhibited. These inhibitory potencies differed widely among the quinolones examined. The Dixon plots showed that a newly developed difluorinated quinolone, NY-198 [1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid hydrochloride], competitively inhibits the receptor bindings of [3H]GABA and [HJmuscimol. In conclusion, our findings suggest that the inhibition of GABA binding to receptors (including uptake sites) in the brain may be involved in the induction of epileptogenic neurotoxicities by quinolones.
Quinolonecarboxylic acid derivatives (quinolones) have been used primarily in the treatment of urinary infections. Most of these antibacterial agents have been shown to cause possible neurotoxic effects, such as headache, dizziness, nausea, vomiting, and paroxysmal epilepsy. As indicated by these side effects on the central nervous system and the occurrence of measurable concentrations in the brain after oral or intravenous administration (7, 13, 14, 16) , these quinolones are considered to penetrate the blood-brain barrier. However, the mechanism of the quinolone-induced effects on the central nervous system is unknown.
The convulsant actions of penicillins and cephalosporins have been related to the reduction of y-aminobutyric acid (GABA) release from nerve terminals or to the inhibition of the binding of GABA to its receptor sites (1, 5, 10) . GABA is a major inhibitory neurotransmitter in the mammalian central nervous system. The epileptogenic neurotoxicity of quinolones and the inhibitory effects of penicillins and cephalosporins on GABA receptor binding prompted us to examine the effects of quinolones, including [1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4oxo-3-quinolinecarboxylic acid hydrochloride], a newly developed difluorinated quinolone (9) (Fig. 1) , on [3H]GABA binding to its receptor sites, i.e., sodium-dependent (+Na) and sodium-independent (-Na) receptor sites for GABA, in rat synaptic plasma membranes in vitro. To discriminate the interaction of quinolones with GABAA sites from that with GABAB sites, [3H]muscimol (a GABAA agonist) was also used. Furthermore, we attempted to correlate the inhibitory potencies of quinolones for -Na binding of GABA with the lipophilic characters of the compounds.
MATERIALS AND METHODS
Drugs and reagents. 4-Amino-n-[2,3-3H]butyric acid (GABA) was purchased from Amersham International Ltd., Buckinghamshire, United Kingdom, and [methylene-3H(N)] muscimol was purchased from New England Nuclear Corp., * Corresponding author. Boston, Mass. (+)-Baclofen was supplied from Shionogi & Co., Ltd., Osaka, Japan. Pipemidic acid, ciprofloxacin, norfloxacin, enoxacin, and NY-198 were synthesized in the Central Research Laboratory, Hokuriku Seiyaku Co., Ltd., Fukui, Japan. Nalidixic acid and ofloxacin were kindly supplied by Daiichi Seiyaku Co., Ltd., Tokyo, Japan, and cinoxacin was supplied by Shionogi & Co., Ltd. The purities of these quinolones were found to be more than 99.5% by high-performance liquid chromatography. All other reagents were commercial products of analytical grade and were used without further purification. Distilled, deionized water was used throughout the experiments.
Preparation of synaptic plasma membranes. Synaptic plasma membranes were prepared by the method of Zukin et al. (18) from the brains of Sprague-Dawley rats (Nihon Clea, Tokyo, Japan) weighing 230 to 270 g. For the study on sodium-independent (-Na) binding of [3H]GABA or [3H]muscimol, the membrane pellets were frozen and kept at -70°C for at least 20 h before binding experiments. In contrast, for the study on sodium-dependent (+Na) binding of [3H]GABA, the freshly prepared pellets were suspended in distilled water, maintained at 25°C for 20 min, and centrifuged at 48,000 x g for 10 min, and the pellets were suspended in 50 mM Tris citrate buffer (pH 7.1) (buffer A).
Effect of quinolones on sodium-independent (-Na) bindings of GABA and muscimol. Aliquots (1 ml) of synaptic plasma membranes (1 mg of protein per ml) were incubated at 4°C for 20 min in buffer A containing [3H]GABA (15 nM) or [3H]muscimol (7.5 nM) alone or in the presence of various concentrations of unlabeled quinolones. After incubation, the reaction was terminated by filtration under low vacuum through Whatman GF/C filters. The filters were then washed four times with 5 ml of ice-cold buffer A. The radioactivity on the filters was determined in 10 ml of a scintillation cocktail (670 ml of toluene, 330 ml of Triton X-100, 5.0 g of DPO [2,5-diphenyloxazole], and 0.3 g of POPOP [1,4-bis(5phenyloxazolyl)benzene]) by using a liquid scintillation counter (LSC-1000; Aloka Co., Ltd., Tokyo, Japan). Nonspecific binding was determined in the presence of a large excess (1 mM) of unlabeled GABA or muscimol. To examine Bindings of these radiolabeled tracers were determined in quintuplicate throughout the experiments. Protein was measured by a modified Lowry method (3). Effect of quinolones on sodium-dependent (+Na) binding of GABA. Aliquots (1 ml) of synaptic plasma membranes (1 mg of protein per ml) were incubated at 4°C for 20 min in buffer A containing 15 nM [3H]GABA alone or in the presence of 1 mM quinolones (0.1 mM in the case of ciprofloxacin, because of its low solubility), 100 mM NaCl, 10 ,uM muscimol, and 1 mM baclofen. Muscimol and baclofen were used to suppress the -Na binding of GABA to GABAA and GABAB sites, respectively. Nonspecific binding was determined in the presence of a large excess (1 mM) of unlabeled GABA. The subsequent procedure was the same as that described above.
Data analysis. Specific binding was obtained by subtracting nonspecific binding from total binding. All results from binding experiments were expressed as either the concentration of receptor-bound and unbound radiolabeled ligands or the specific binding (SB) percentage of the radiolabeled ligand, which is the ratio of the specific binding in the presence of an unlabeled quinolone to that in its absence (control). The inhibition data were submitted to nonlinear least-squares regression analysis by using a computer program, NONLIN74 (12), on a FACOM M-360AP digital computer (Information Processing Center, Kanazawa University, Kanazawa, Japan) to give binding parameters according to the following equation: SB (%) = (1 + Ka Cf)l(l + Ka * Cf + Ki* CQ) x 100 (1) where Ka and Cf represent the binding constant (iLM-1) and the concentration (,uM) of unbound radiolabeled ligand, respectively; Ki and Ci represent the inhibition constant (,uM-1) and the total concentration (,uM) of the inhibitor, respectively.
Measurement of oil-water partition of quinolones. To ex-amine the relationship between the lipophilicity and inhibition constants for [3H]GABA binding among the various quinolones, the apparent partition coefficient (Papp) of each quinolone tested was measured at 37°C in n-octanol-50 mM sodium phosphate buffer (pH 7.0; ionic strength, 0.15) by the method of Tsuji et al. (17) .
RESULTS
Effect of quinolones on sodium-independent (-Na) bindings of GABA and muscimol. The rat brain membrane fraction prepared in the present study had high affinity (Ka = 25.0 ,uM-') for GABA, and the receptor density (n) on the membranes was 120 fmol/mg of protein. The Ka value was comparable to the value reported previously (Ka = 44 puM-1;
2). However, the binding capacity was somewhat smaller than the reported value (n = 580 fmol/mg of protein; 2), possibly due to the difference in the methods of separating bound and free radioligands between the previous report (centrifugation) and the present study (rapid filtration). The ratio of the specific binding to the nonspecific binding in the absence of quinolones was 3.5 for [3H]GABA (15 nM) and 3.8 for [3H]muscimol (7.5 nM). Figures 2A and B show representative curves of inhibition by quinolones (nalidixic acid, norfloxacin, and NY-198) of [3H]GABA and [3H]muscimol bindings to synaptic plasma membranes, respectively. The quinolones showed concentration-dependent inhibition of the specific bindings of GABA and muscimol. The IC50 (concentration required to inhibit 50% of the total binding) values differed greatly among the quinolones tested. The order of IC50s for [3H]GABA binding was norfloxacin < NY-198 = cinoxacin = pipemidic acid < enoxacin < ofloxacin < nalidixic acid. The IC50 of ciprofloxacin could not be evaluated because of the low solubility of the drug. Similarly, the order of IC50s for [3H]muscimol binding was norfloxacin < NY-198 < nalidixic acid. Figures 3A and B Fig. 2 ) to equation 1 by nonlinear least-squares regression analysis using the computer program NONLIN74 (12) . The Ki values of NY-198 obtained graphically from the Dixon plots ( Fig. 3 ) are in good agreement with the values shown in Table 1 .
Effect of quinolones on sodium-dependent (+Na) binding of GABA. Figure 4 shows the effects of various quinolones on +Na binding of [3H]GABA to carrier proteins in the presence of large excesses of muscimol and (+)-baclofen. In terms of the fraction displaced by 1 mM quinolones (0.1 mM in the case of ciprofloxacin), the order of potencies to inhibit the +Na binding of GABA was enoxacin > norfloxacin > cinoxacin > ofloxacin > pipemidic acid = NY-198. Nalidixic acid and ciprofloxacin apparently did not inhibit the GABA binding at the concentrations of 1 and 0.1 mM, respectively. Measurement of oil-water partition of quinolones. Papps of quinolones were determined and are shown in Table 1 . The Papp values showed a wide variation, indicating that the lipophilicity differed greatly among the quinolones.
DISCUSSION
The present study was undertaken to examine the effects of some classical and new derivatives of quinolones on the specific binding of GABA to rat synaptic plasma membranes in vitro, with the aim of gaining some insight into the mechanism of the neurotoxic effects of quinolones reported in clinical therapeutics.
It was found that various quinolones show concentrationdependent inhibition of the -Na bindings of [3H]GABA and [3H]muscimol to synaptic plasma membranes, suggesting the existence of a pharmacological interaction (antagonism) between endogenous GABA and exogenously administered quinolones at the postsynaptic receptor sites in vivo. Norfloxacin showed the greatest inhibitory effect (Fig. 2B ). The observation that NY-198, a new quinolonecarboxylic acid derivative, competitively inhibited the specific bindings of GABA and muscimol to the receptor sites suggests a competitive interaction between GABA and the quinolones generally. Because of this presumed competitive nature of the inhibition, the Ki values (Table 1 ) of the quinolones were obtained by fitting the curves of inhibition of [3H]GABA by various quinolones to equation 1 (the equation expressing competitive inhibition) by nonlinear least-squares regression analysis. The Ki values thus obtained were slightly higher than the Ki values of P-lactam antibiotics that inhibit the specific binding of GABA to synaptic plasma membranes (10) . Further experimental evidence should be accumulated to confirm the mechanism of the inhibitory effect of quinolones on GABA binding. In contrast to GABAA sites, relatively little is known about the physiological role of the GABAB sites to which baclofen binds stereospecifically (8) , so that the effect of quinolones on GABA binding to GABAB sites was not examined in the present study.
It was also found that +Na binding of GABA was inhibited by various quinolones tested. The +Na binding of b Measured in n-octanol-50 mM sodium phosphate buffer (pH 7.0) at 37°C.
Each value represents the mean ± standard error of the mean (n = 4). c ND, Not detected because of the low solubility of ciprofloxacin. d -, Not determined. [3H]GABA (15 nM) and 1 mM quinolone (0.1 mM in the case of ciprofloxacin, because of its low solubility) were incubated with synaptic plasma membrane suspensions for 20 min at 4°C in the presence of 100 mM NaCl, 10 ,uM muscimol, and 1 mM (±)-baclofen. Each column and bar represents the mean ± standard deviation (n = 5).
GABA represents attachment to the uptake sites (15) which transport GABA into nerve terminals and glia (11) . Consequently, the inhibition of the +Na binding of GABA by quinolones may reduce release of GABA from nerve terminals through depletion of GABA storage. Enoxacin showed the largest inhibitory effect on +Na binding (Fig. 4) . On the basis of the data in Table 1 and Fig. 4 , there was a poor correlation (r = 0.67, P < 0.01) between the inhibitory potencies of quinolones on the GABA bindings to receptors and uptake sites, in agreement with a previous report (6) on the different structural characteristics of GABA receptors and GABA uptake mechanisms. Borea and Bonora (4) examined the relationship between the binding affinities and lipophilic character (expressed in terms of chromatographic Rf values) of various benzodiazepines and found a parabolic correlation curve. They explained this by proposing that the primary benzodiazepinereceptor interaction is determined by electrostatic interaction acting via a hydrogen bonding mechanism, while the descending branch of the parabola is due to nonspecific adsorption on the lipoidal membranes which increases with the increasing lipophilic character of the drug. Similarly, the relationship between the lipophilicity (Papp) and the receptor affinity (K, values) of the quinolones, which appears to be an inverse one based on the data in Table 1 , may be interpreted in terms of possible electrostatic interactions between GABA receptors and the quinolones.
The maximal concentrations of quinolones in the brain after oral or intravenous administration of single 20to 50mg/kg (body weight) doses to rats were reported to be in the range of 0.5 to 50 ,uM (7, 13, 14, 16) , indicating that quinolones can penetrate the blood-brain barrier to some extent. These reported values, however, were determined as average values among the various brain regions and do not necessarily reflect the actual extracellular concentrations in specific areas of the brain. Moreover, little information is available as to the effect of repeated doses on the drug concentration in the brain. Therefore, we do not know whether the extracellular concentrations of quinolones in the brain or in specific regions of the brain actually reach the lIKi values, which range from 0.07 mM (norfloxacin) to 8.5 mM (nalidixic acid), when the neurotoxic effects of these drugs appear.
In conclusion, our findings suggest that the inhibition of GABA binding to receptors (including uptake sites) in the brain may be involved in the induction of epileptogenic neurotoxicities by quinolones.
